Patents Assigned to Rheinische Friedrich-Wilhelms-Universitat
  • Patent number: 8815503
    Abstract: The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IL-12-inducing activity to a single-stranded RNA oligonucleotide. The present invention also provides single-stranded RNA oligonucleotides, including antisense RNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: August 26, 2014
    Assignee: Rheinische Friedrich-Wilhelms-Universitat Bonn
    Inventors: Gunther Hartmann, Veit Hornung
  • Publication number: 20140066409
    Abstract: The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, particularly for use as an antibiotic.
    Type: Application
    Filed: December 13, 2011
    Publication date: March 6, 2014
    Applicants: UNIVERSITÄT KONSTANZ, RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN
    Inventors: Günter Mayer, Christina Elsbeth Luense, Valentin Wittmann, Magnus S. Schmidt
  • Patent number: 8623593
    Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: January 7, 2014
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Evi Kostenis, Andreas Spinrath, Stephanie Hennen, Lucas Peters, Christa E. Muller, Rhalid Akkari, Younis Baqi, Kirsten Ritter
  • Publication number: 20130344486
    Abstract: The present invention relates to methods of diagnosing a breast carcinoma, determining the prognosis of a patient diagnosed with breast carcinoma and determining the efficacy of a treatment regimen of breast carcinoma in a patient, using Calponin-h2 and/or CALML 5 as markers. Furthermore, the invention relates to a kit and a marker panel for use in these methods.
    Type: Application
    Filed: February 28, 2012
    Publication date: December 26, 2013
    Applicant: Rheinische Friedrich-Wilhelms-Universitat Bonn
    Inventors: Manuel Debald, Gisela Walgenbach-brunagel
  • Publication number: 20130338374
    Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.
    Type: Application
    Filed: March 4, 2013
    Publication date: December 19, 2013
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Evi Kostenis, Andreas Spinrath, Stephanie Hennen, Lucas Peters, Christa E. Muller, Rhalid Akkari, Younis Baqi, Kirsten Ritter
  • Publication number: 20130158093
    Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.
    Type: Application
    Filed: February 25, 2013
    Publication date: June 20, 2013
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventor: Rheinische Friedrich-Wilhelms-Universität Bonn
  • Patent number: 8404436
    Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: March 26, 2013
    Assignee: Rheinische Friedrich-Wilhelms-Universitat Bonn
    Inventors: Evi Kostenis, Andreas Spinrath, Stephanie Hennen, Lucas Peters, Christa E. Muller, Rhalid Akkari, Younis Baqi, Kirsten Ritter
  • Publication number: 20130059899
    Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.
    Type: Application
    Filed: February 28, 2012
    Publication date: March 7, 2013
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN
    Inventors: Evi Kostenis, Andreas Spinrath, Stephanie Hennen, Lucas Peters, Christa E. Müller, Rhalid Akkari, Younis Baqi, Kirsten Ritter
  • Patent number: 8163788
    Abstract: The invention relates to a pharmaceutical composition and the use thereof, wherein the pharmaceutical composition contains compounds selected from a group of general formulas (5), (6), (7) and (8) and/or enantiomers, diastereomers or the pharmaceutically acceptable salts thereof. The pharmaceutical composition is used for treating autoimmune and tumoral diseases and/or for immunosuppresion.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: April 24, 2012
    Assignee: Rheinische Friedrich-Wilhelms Universitat Bonn
    Inventors: Michael Famulok, Waldemar Kolanus, Markus Hafner, Imke Grune, Barbara Tappertzhofen, Mirko Theis
  • Publication number: 20110312893
    Abstract: The invention relates to a method for isolating neural cells using tenascin-R compounds, tenascin-R fragments particularly suited for said method and tenascin-R fusion proteins, to recombinant preparation of said tenascin-R compounds, and to a kit for carrying out said method and to the use of said method for preparing high-purity neural cell populations. The invention further relates to antibodies suitable for detecting and isolating tenascin-R compounds.
    Type: Application
    Filed: September 16, 2009
    Publication date: December 22, 2011
    Applicant: RHEINISCHE -FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Penka Pesheva, Rainer Probstmeier
  • Publication number: 20110260814
    Abstract: Disclosed is a device for generating a uniform magnetic field and to an optimization method for magnetic fields in a sample space, the method providing specifications for producing such a device. The device comprises at least one field coil for generating the magnetic field and the turns of the field coil are continuously wound around the sample space and the turn diameter of the field coil changes continuously at least in a portion of the field coil along the longitudinal axis of the sample space. To this end, the correction of non-uniformities in the magnetic field caused by the finite length of the field coil is distributed over the entire field coil. In this way, the device can be implemented more easily and precisely than with the correction coils used according to the prior art for correcting non-uniformities.
    Type: Application
    Filed: November 30, 2009
    Publication date: October 27, 2011
    Applicants: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN, FORSCHUNGSZENTRUM JÜLICH GMBH
    Inventors: Andrea Raccanelli, Rolf Krause
  • Publication number: 20110224279
    Abstract: The present invention relates to a nucleic acid molecule and a pharmaceutical or diagnostic composition for the therapeutic and/or prophylactic treatment or diagnosis of cancer and/or metastasis thereof, comprising a nucleic acid molecule, or an amino acid sequence related to Trim71 and/or its mammalian and non mammalian orthologs and/or a nucleic acid sequence of the gene encoding for Trim71 and/or its mammalian and non mammalian orthologs.
    Type: Application
    Filed: February 27, 2009
    Publication date: September 15, 2011
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITAT
    Inventors: Waldemar Kolanus, Michael Karl Hoch, Joachim L. Schultze, Birgit Loeer
  • Publication number: 20110159012
    Abstract: The invention relates to a process for isolating neural cells using tenascin-R compounds, tenascin-R fragments and tenascin-R fusion proteins that are particularly suitable for such process, the recombinant preparation of such tenascin-R compounds, and a kit for performing this process, and the use of the process for preparing highly pure neural cell populations. The invention further relates to antibodies suitable for the detection and isolation of tenascin-R compounds.
    Type: Application
    Filed: December 16, 2005
    Publication date: June 30, 2011
    Applicant: RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventor: Penka Pesheva
  • Publication number: 20110104691
    Abstract: The present invention relates to methods for testing for a predisposition or presence of androgenetic alopecia comprising testing a sample obtained from a prospective patient or from a person suspected of carrying a predisposition for androgenetic alopecia. The invention also relates to a genetic marker for androgenetic alopecia characterised in that the genetic marker is located in a chromosomal region of human chromosome 20p11 and wherein the genetic marker is selected from the group consisting of a single nucleotide polymorphism (SNP), variable number of tandem repeat (VNTR), microsatellites or short tandem repeats (STR). Further, the invention relates to a diagnostic composition for the detection of androgenetic alopecia or a predisposition therefore as well as to a kit.
    Type: Application
    Filed: April 7, 2009
    Publication date: May 5, 2011
    Applicants: LIFE & BRAIN GMBH, HEINRICH-HEIN-UNIVERSITAT DUSSELDORF, RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT
    Inventors: Markus M. Nöthen, Felix F. Brockschmidt, Axel Hillmer, Roland Kruse
  • Publication number: 20110070421
    Abstract: An object having a surface that has: filaments having a length of from 30 to 6000 ?m, a diameter to length ratio of from 1:10 to 1:20, and are bound to the surface with at least one front face thereof; wherein the distance between two neighboring filaments on the surface is such that the ratio of such distance to the length of the filaments is from 1:3 to 1:10; the filaments have an elasticity of from 104 to 1010 N/m2; the surface of the filament is at least partially hydrophobic, so that the contact angle between a filament and water is greater than 100°, characterized in that the filaments are structurally or chemically anisotropic.
    Type: Application
    Filed: January 30, 2009
    Publication date: March 24, 2011
    Applicant: Rheinische Friedrich-Wilhelms-Universitat Bonn
    Inventors: Zdenek Cerman, Boris F. Striffler, Sabine Wiersch, Wilhelm Barthlott
  • Patent number: 7790456
    Abstract: The invention relates to a process for cultivating undifferentiated stem cells in suspension and in particular to a method for cultivating stem cells on microcarriers in vessels. The method enables stem cells to be cultivated in a scalable process for the first time, without losing their pluripotentiality. Different types of vessels are suitable for cultivation, such as e.g. spinners and bioreactors. The option of precisely setting the cultivation conditions in said vessels aids the process of obtaining a pluripotentiality of the stem cells. the inventive method also permits large yields of stem cells of an unvarying quality to be produced.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: September 7, 2010
    Assignee: Rheinische Friedrich-Wilhelms-Universitat
    Inventors: Stefanie Terstegge, Oliver Brüstle
  • Publication number: 20100210654
    Abstract: The present invention relates to novel P2Y12 receptor antagonists useful for treating, alleviating and/or preventing diseases and disorders related to P2Y12 receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The present invention is further directed to the use of these compounds, alone or in combination with other therapeutic agents, for the alleviation, prevention and/or treatment of diseases and disorders, especially the use as antithrombotic agents for inhibiting platelet aggregation.
    Type: Application
    Filed: March 7, 2008
    Publication date: August 19, 2010
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN
    Inventors: Christa E. Müller, Younis Baqi
  • Publication number: 20100204182
    Abstract: The present invention provides ectonucleotidase inhibitors represented by the following formula, including ecto-nucleotide triphosphate diphosphohydrolase (NTPDase) inhibitors and ecto-5?-nucleotidase (ecto-5?-NT) inhibitors, namely nucleotide mimetics as selective NTPDase or ecto-5?-NT inhibitors. It also provides methods for preparations of said compounds. Furthermore provided are pharmaceutical and diagnostic compositions comprising said compounds, and the use of said compounds in a medicament for treating diseases associated with ectonucleotidase activity and/or P1 or P2 receptors.
    Type: Application
    Filed: May 24, 2007
    Publication date: August 12, 2010
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN
    Inventors: Christa E. Müller, Andreas Brunschweiger, Jamshed Iqbal
  • Publication number: 20100179225
    Abstract: A method is provided, comprising administering at least one guanylhydrazone or salt thereof or a combination thereof to a subject to prevent or ameliorate in said subject at least one of postoperative intestinal inflammation, postoperative ileus, ischemia reperfusion injury, or a combination thereof.
    Type: Application
    Filed: September 15, 2009
    Publication date: July 15, 2010
    Applicants: CYTOKINE PHARMASCIENCES, INC., RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN
    Inventors: Jörg KALFF, Sven Wehner, Nico Schäfer, Thais M. Sielecki-Dzurdz
  • Publication number: 20100048501
    Abstract: A phosphorylated A2A receptor agonist providing agonist properties on the A2A receptor after dephosphorylation the phosphorylated A2A receptor agonist comprises a ribosyl moiety and a purine moiety and being phosphorylated at the 5?-position of the ribose moiety except adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP), a medicament containing the compound of the invention including ADP and the use of the compound of the invention including ATP and ADP for several medical indications e. g. inflammatory events. In particular, compounds of formula (I) are also disclosed.
    Type: Application
    Filed: March 21, 2007
    Publication date: February 25, 2010
    Applicants: Heinrich-Heine-Universitat Dusseldorf, Rheinische Friedrich-Wilhelms-Universitat Bonn
    Inventors: Jurgen Schrader, Christa Muller, All El-Tayeb, Jamshed Iqbal